Lenz Therapeutics Inc. is a late-stage biopharmaceutical company focused on developing and commercializing innovative therapies to improve vision. Its product candidate includes LNZ100 and LNZ101, are preservative-free, single-use, once-daily, aceclidine-based eye drops currently in Phase 3 clinical trials for the treatment of presbyopia. Lenz Therapeutics Inc., formerly known as Graphite Bio Inc., is based in SOUTH SAN FRANCISCO, Calif.
| Revenue (Most Recent Fiscal Year) | -- |
| Net Income (Most Recent Fiscal Year) | $-49.77M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | -- |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 4.30 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -- |
| Net Margin (Trailing 12 Months) | -- |
| Return on Equity (Trailing 12 Months) | -23.74% |
| Return on Assets (Trailing 12 Months) | -22.65% |
| Current Ratio (Most Recent Fiscal Quarter) | 23.09 |
| Quick Ratio (Most Recent Fiscal Quarter) | 23.09 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $7.42 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-0.53 |
| Earnings per Share (Most Recent Fiscal Year) | $-2.34 |
| Diluted Earnings per Share (Trailing 12 Months) | $-1.77 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 28.15M |
| Free Float | 26.20M |
| Market Capitalization | $844.39M |
| Average Volume (Last 20 Days) | 0.23M |
| Beta (Past 60 Months) | 0.42 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 6.90% |
| Percentage Held By Institutions (Latest 13F Reports) | 54.32% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |